SUBSCRIBE
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
- Cybersecurity
MARKETS
HOW-TO
VIDEO
- Audio
Courses
- Personal Finance Essentials
- Fundamentals of Investing

Terms Of Use
Privacy Policy
Advertise
Reprints
Customer Service
Data
Topic Archive
Subscriptions
Privacy Settings

JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
COURSES

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

Forgot your password?

Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

I agree to TheMaven's Terms and Policy

Already have an account? Login here

Alerts
|
Newsletters

JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
COURSES

Biotechnology

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Therapeutics Surges on FDA Approval of Muscular Dystrophy Treatment

By M. Corey Goldman

Audentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase

Audentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase

By Rob Lenihan

AbbVie Affirmed Overweight at Piper Jaffray on Potential of Arthritis Drug

AbbVie Affirmed Overweight at Piper Jaffray on Potential of Arthritis Drug

By Tony Owusu

Shares of CRISPR Therapeutics Fall in After Hours Trading on Share Offering

Shares of CRISPR Therapeutics Fall in After Hours Trading on Share Offering

By Tom Bemis

Medtronic Wavers After Posting Earnings Beat; Cardiac Unit Misses Estimates

Medtronic Wavers After Posting Earnings Beat; Cardiac Unit Misses Estimates

By Rob Lenihan

Abiomed Shares Take Beating After Studies Question Heart Pump

Abiomed Shares Take Beating After Studies Question Heart Pump

By Scott Van Voorhis

AbbVie Selling Up to $28 Billion in Bonds to Acquire Allergan: Report

AbbVie Selling Up to $28 Billion in Bonds to Acquire Allergan: Report

By Scott Van Voorhis

Amgen at 52-Week Highs Bumps Against Resistance, Remains a Long-Term Hold

Amgen at 52-Week Highs Bumps Against Resistance, Remains a Long-Term Hold

By Nicholas Ward

Myriad Genetics Plummets as Earnings Trail Forecasts, Guidance Is Slashed

Myriad Genetics Plummets as Earnings Trail Forecasts, Guidance Is Slashed

By Dan Weil

Mylan Posts Stronger-Than-Expected Third-Quarter Profit, Reiterates Forecast

Mylan Posts Stronger-Than-Expected Third-Quarter Profit, Reiterates Forecast

By M. Corey Goldman

Mylan Doles Out the Right Prescription for Investors

Mylan Doles Out the Right Prescription for Investors

AbbVie Affirmed Overweight at Piper Jaffray on Potential of Arthritis Drug

AbbVie Posts Stronger-Than-Expected Earnings, Lifts Forecast

By M. Corey Goldman

Alphabet's Share Price Weakness Is an Opportunity to Buy

Alphabet's Share Price Weakness Is an Opportunity to Buy

By Daniel Martins

Danaher Shares Surge After Dental Spinoff Plan, Solid Q2 Earnings

Danaher Beats Third-Quarter-Earnings Forecasts but Shares Ease on Guidance Miss

By Rob Lenihan

Thermo Fisher to Buy Gene-Therapy Company Brammer Bio for $1.7 Billion

Thermo fisher soars after earnings beat by lab equipment maker

By Scott Van Voorhis

Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal

Alexion Rises After Drug Developer Beats Earnings Expectations

By Scott Van Voorhis

Prepare for Volatility Around Biogen Ahead of Alzheimer's Presentation: Leerink

Is Biogen Stock a Buy or Sell After Tuesday's Choppy Rally?

By Bret Kenwell

Kyle Turley Says He'd Still Be Playing Professional Football If NFL Allowed CBD

Former Saints Offensive Lineman Kyle Turley Says He'd Still Be Playing If NFL

Why Kyle Turley Believes CBD Can Solve Opioid Crisis for Professional Athletes

Why Kyle Turley Believes CBD Can Solve Opioid Crisis for Professional Athletes

Kyle Turley Says He'd Still Be Playing If NFL Allowed CBD

Kyle Turley Says He'd Still Be Playing If NFL Allowed CBD

Kyle Turley Looks Back at His Time in the NFL, Struggle with Opioids

Kyle Turley

Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal

Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal

By Brenda Bouw

5 Best-Positioned Biotech Stocks on Brexit Volatility

Reata Shares Jump on Drug-Study Results

By Tom Bemis

Google Reportedly Pondering Changes to Political Ad Policy

Alphabet Is Cheap Now, but It Won't Remain This Inexpensive Forever

By Michael Wiggins De Oliveira

Terms Of Use
Privacy Policy
Advertise
Reprints
Customer Service
Data
Topic Archive
Subscriptions

© 2019 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.